Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • France
    • +34 96 390 53 10 Request Information
    • +34 96 390 53 10 Request Information
    FranceFrance
    • France
      • Part of brands: |
        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        Genomics Precision Diagnostic > Hematology Precision Panel > Von Willebrand Disease Precision Panel

        Von Willebrand Disease Precision Panel

        Von Willebrand disease (VWD) is the most common inherited bleeding disorder with a heterogeneous clinical presentation and genetic background.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Von Willebrand disease (VWD) is the most common inherited bleeding disorder with a heterogeneous clinical presentation and genetic background. The main feature relies on a deficiency or dysfunction of the protein named von Willebrand factor (vWF) resulting in an impaired primary homeostasis where platelets play a crucial role. Von Willebrand factor serves as a mediator for platelet adhesion during vascular injury and a reservoir and stabilizer for protein factor VIII, the absence of this protein causes a qualitative platelet disorder. Significant variability exists among family members that suffer from this disease depending on the amount on functioning circulating von Willebrand factor. 

        • The Igenomix Von Willebrand Disease Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of recurrent bleeding ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

        Indication

        • The Igenomix Von Willebrand Disease Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
          • Easy bruising 
          • Nosebleeds 
          • Gingival bleeding 
          • Severe hemorrhage 
          • Menorrhagia 
          • Jaundice 
          • Splenomegaly 
          • Hematomas 
          • Petechiae  
          • Ecchymosis  

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of treatment with a multidisciplinary team in the form of medical treatment with desmopressin, recombinant therapy and prevention of events that potentially increase risk of bleeding. 
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
        • Improvement of delineation of genotype-phenotype correlation. 

        Genes & Diseases

        See all genes and diseases

        GENE 

        OMIM DISEASES 

        INHERITANCE* 

        % GENE COVERAGE (20X) 

        HGMD** 

        F8 

        Hemophilia A 

        X,XR,G 

        99.89 

        – 

        GP1BA 

        Bernard-Soulier
        Syndrome, Nonarteritic
        Anterior Ischemic
        Optic Neuropathy,
        Von Willebrand Disease,
        Thrombocytopenia
         

        AD,AR 

        99.98 

        73 of 73 

        GP1BB 

        Bernard-Soulier
        Syndrome, 22q11.2
        Deletion Syndrome,
        Thrombocytopenia
         

        AR 

        74.08 

        26 of 50 

        GP9 

        Bernard-Soulier 
        Syndrome 

        AR 

        99.96 

        41 of 41 

        ITGA2B 

        Glanzmann Thrombasthenia,
         
        Thrombocytopenia 

        AD,AR 

        100 

        237 of 239 

        ITGB3 

        Glanzmann Thrombasthenia, 
        Thrombocytopenia 

        AD,AR 

        99.44 

        178 of 179 

        NBEAL2 

        Gray Platelet 
        Syndrome 

        AR 

        99.74 

        51 of 51 

        VWF 

        Von Willebrand 
        Disease 

        AD,AR 

        98 

        933 of 1001 

         * Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial 

        ** HGMD: Number of clinically relevant mutations according to HGMD 

        Methodology

        References

        See scientific referrals

        Veyradier, A., Boisseau, P., Fressinaud, E., Caron, C., Ternisien, C., & Giraud, M. et al. (2016). A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease. Medicine, 95(11), e3038. doi: 10.1097/md.0000000000003038 

        Sharma, R., & Flood, V. H. (2017). Advances in the diagnosis and treatment of Von Willebrand disease. Blood, 130(22), 2386–2391. https://doi.org/10.1182/blood-2017-05-782029 

        Ng, C. J., & Di Paola, J. (2018). von Willebrand Disease: Diagnostic Strategies and Treatment Options. Pediatric clinics of North America, 65(3), 527–541. https://doi.org/10.1016/j.pcl.2018.02.004 

        Swami, A., & Kaur, V. (2017). von Willebrand Disease: A Concise Review and Update for the Practicing Physician. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 23(8), 900–910. https://doi.org/10.1177/1076029616675969 

        Nichols, W. L., Hultin, M. B., James, A. H., Manco-Johnson, M. J., Montgomery, R. R., Ortel, T. L., Rick, M. E., Sadler, J. E., Weinstein, M., & Yawn, B. P. (2008). von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia : the official journal of the World Federation of Hemophilia, 14(2), 171–232. https://doi.org/10.1111/j.1365-2516.2007.01643.x 

        Goodeve, A. (2016). Diagnosing von Willebrand disease: genetic analysis. Hematology, 2016(1), 678-682. doi: 10.1182/asheducation-2016.1.678 

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        Fertilité

        Fertilité
        Éviter les maladies génétiques

        Test prénatal non-invasif

        Pour voir le certificat d'accréditation, l'annexe technique associée et la liste des tests accrédités, cliquez sur ce lien.

        Nos services

        Nos services
        Patients
        D'envoyer les échantillons
        Manuel d'utilisateur

        À propos d’Igenomix

        À propos d’Igenomix
        Igenomix dans le monde
        Quality
        Work with us

        SUIVRE IGENOMIX

          + 96 390 53 10
        Écrivez-nous
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        France

        [2021] © Igenomix Politique de confidentialité Politique de qualité Note juridique Politique de cookiesActualités et presse 

        Demander des informations


        • reCAPTCHA demo: Simple page

        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        • France
        • +34 96 390 53 10 Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        France
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.